These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 20149324)
21. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J; Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449 [TBL] [Abstract][Full Text] [Related]
22. Rituximab treatment in patients with refractory inflammatory myopathies. Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768 [TBL] [Abstract][Full Text] [Related]
23. Advances in the therapy of idiopathic inflammatory myopathies. Baer AN Curr Opin Rheumatol; 2006 May; 18(3):236-41. PubMed ID: 16582685 [TBL] [Abstract][Full Text] [Related]
24. [The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort]. Szabó K; Nagy-Vincze M; Bodoki L; Hodosi K; Dankó K; Griger Z Orv Hetil; 2016 Apr; 157(15):575-83. PubMed ID: 27039996 [TBL] [Abstract][Full Text] [Related]
25. Rituximab as therapy for refractory polymyositis and dermatomyositis. Noss EH; Hausner-Sypek DL; Weinblatt ME J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475 [TBL] [Abstract][Full Text] [Related]
26. Atypical progressive multifocal leukoencephalopathy in a patient with antisynthetase syndrome. Belhassen-Garcia M; Rábano-Gutiérrez A; Velasco-Tirado V; Romero-Alegria A; Pérez-Garcia ML; Martin-Oterino JA Intern Med; 2015; 54(5):519-24. PubMed ID: 25758081 [TBL] [Abstract][Full Text] [Related]
27. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Marie I; Dominique S; Janvresse A; Levesque H; Menard JF Respir Med; 2012 Apr; 106(4):581-7. PubMed ID: 22280877 [TBL] [Abstract][Full Text] [Related]
28. Rituximab in life threatening antisynthetase syndrome. Vandenbroucke E; Grutters JC; Altenburg J; Boersma WG; ter Borg EJ; van den Bosch JM Rheumatol Int; 2009 Oct; 29(12):1499-502. PubMed ID: 19184665 [TBL] [Abstract][Full Text] [Related]
29. Treatment of the inflammatory myopathies: update and practical recommendations. Hengstman GJ; van den Hoogen FH; van Engelen BG Expert Opin Pharmacother; 2009 May; 10(7):1183-90. PubMed ID: 19405792 [TBL] [Abstract][Full Text] [Related]
30. [Use of anti-B-cell therapy in case of antisynthetase syndrome as the severest subtype of polymyositis/dermatomyositis]. Antelava OA; Khelkovskaia-Sergeeva AN; Tarasova GM; Nikishina NIu; Lopatina NE; Pal'shina SG; Fedina TP; Sazhina EG Ter Arkh; 2014; 86(5):109-15. PubMed ID: 25026812 [TBL] [Abstract][Full Text] [Related]
31. Spontaneous pneumomediastinum secondary to refractory dermatomyositis successfully treated with rituximab. Lee MA; Hutchinson DG Clin Rheumatol; 2010 Aug; 29(8):945-6. PubMed ID: 20195881 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Leclair V; Galindo-Feria AS; Dastmalchi M; Holmqvist M; Lundberg IE Rheumatology (Oxford); 2019 Jul; 58(7):1214-1220. PubMed ID: 30690633 [TBL] [Abstract][Full Text] [Related]
34. Inflammatory myopathies--a review of newly diagnosed patients (2004-2008) in the Counties Manukau region. Gupta R; Gow PJ N Z Med J; 2013 Mar; 126(1370):89-95. PubMed ID: 23474516 [TBL] [Abstract][Full Text] [Related]
35. Successful Treatment of Life-Threatening Interstitial Lung Disease Secondary to Antisynthetase Syndrome Using Rituximab: A Case Report and Review of the Literature. Dasa O; Ruzieh M; Oraibi O Am J Ther; 2016; 23(2):e639-45. PubMed ID: 25830868 [TBL] [Abstract][Full Text] [Related]
36. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672 [TBL] [Abstract][Full Text] [Related]
37. Clinical spectrum of inflammatory myositis in South India--a ten year study. Porkodi R; Shanmuganandan K; Parthiban M; Madhavan R; Rajendran P J Assoc Physicians India; 2002 Oct; 50():1255-8. PubMed ID: 12568209 [TBL] [Abstract][Full Text] [Related]
38. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Jois RN; Masding A; Somerville M; Gaffney K; Scott DG Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180 [TBL] [Abstract][Full Text] [Related]
39. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. Qushmaq KA; Chalmers A; Esdaile JM J Rheumatol; 2000 Dec; 27(12):2855-9. PubMed ID: 11128676 [TBL] [Abstract][Full Text] [Related]
40. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]